Chugai ( Chugai )

Chugai

Chugai's picture

About Chugai

Chugai Pharmaceutical utilizes leading technologies in biopharmaceutical and molecular targeted drug discovery to create innovative drugs.

Chugai press release, blog etc

08/02/2018 - 20:02 Anti-CD20 Monoclonal Antibody RITUXAN , Application for Approval of Additional Indication of CD20-Positive Chronic Lymphocytic Leukemia
07/26/2018 - 12:02 Chugai Pharmabody Research Pte. Ltd., Chugais Research Subsidiary
07/26/2018 - 10:51 Construction of a New Synthetic Research Building to Enhance Process Development for Small and Middle Molecule APls
07/17/2018 - 00:57 Chugai to In-license ROS1/TRK Inhibitor Entrectinib
07/02/2018 - 12:20 Humanized Anti-CD20 Monoclonal Antibody, GAZYVA Intravenous Infusion 1000 mg, Approved for the Treatment of CD20-Positive Follicular Lymphoma
06/05/2018 - 11:20 Chugais HEMLIBRA Receives Priority Review Status from U.S. FDA for Hemophilia A without Inhibitors
05/28/2018 - 19:52 Humanized Anti-Human IL-6 Receptor Monoclonal Antibody ACTEMRA , Application for Approval of Additional Indication of Cytokine Release Syndrome Induced by Treatment with CAR-T Cell Therapy
05/24/2018 - 01:29 Humanized Anti-Human IL-6 Receptor Monoclonal Antibody ACTEMRA , Application for Approval of Additional Indication of Adult Onset Still's Disease
05/21/2018 - 23:50 Launch of HEMLIBRA Subcutaneous Injection for the Treatment of Hemophilia A
05/20/2018 - 22:22 Chugai Presents Results of Two Pivotal Phase III Studies
05/15/2018 - 23:31 Chugais ALK Inhibitor Alecensa Approved for the Treatment of First Line Therapy on ALK-Positive Non-Small Cell Lung Cancer in Taiwan
05/09/2018 - 23:40 Chugais Anti-IL-31 Receptor A Humanized Monoclonal Antibody nemolizumab, Long Term Data from Global Phase II Study Published in Journal of Allergy and Clinical Immunology Online
04/26/2018 - 02:01 Chugai Files Applications for HEMLIBRA for the Treatment of Hemophilia A without Factor VIII Inhibitors and for Extension of Dosing Interval
04/20/2018 - 00:23 Notice of Completion of Disposal of Treasury Shares as Restricted Stock Compensation Plan
04/17/2018 - 22:10 Launch of the Anti-Cancer Agent / a Humanized Anti-PD-L1 Monoclonal Antibody TECENTRIQ
04/11/2018 - 02:19 Waiver of Claims in Patent Infringement Lawsuit
03/23/2018 - 02:10 Anti-Coagulation Factor IXa/X Humanized Bispecific Monoclonal Antibody HEMLIBRA Subcutaneous Injection Approved in Japan
03/21/2018 - 21:40 New Drug Application of Eldecalcitol, an Active Vitamin D 3 Derivative, for the Treatment of Osteoporosis Accepted in China